Follow The Filings

ACRS Aclaris Therapeutics Inc.

Health Care, filed as ACLARIS THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 1.2%
  • $8.5M

Who owns this now

Largest portfolio weights among holders, up to 1.2% (Palo Alto Investors). Not free-float ownership.

  1. Palo Alto Investors 1.2%

Who owns ACRS

Sorted by value, long equity only, as of 2026 Q2.

History
Palo Alto Investors 1.2% Hold 1,613,430 $8.5M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by ACRS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ACRS insider trades
  • None no insider bought on the open market
  • $1.4M sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Braden Michael Leonard 10% owner
    Sale
    $1.4M 300,000 shares at $4.53 2.1% of stake
    Traded Apr 23 Filed Apr 27
    ↗

Also filed in the last 12 months, not counted as buying or selling: 24 option exercises and 14 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 24 shown.

Filed Form Detail Links
424B5 Filing Doc
8-K 1.01,9.01 Filing Doc
8-K 2.02,7.01,8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 1.01,9.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 7.01 Filing Doc
8-K 7.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $31.25M $18.72M $7.83M
Gross profit * $27.83M $15.93M $5.74M
Gross margin * 89.0% 85.1% 73.3%
Net income -$88.48M -$132.06M -$64.92M
Net margin * -283.1% -705.5% -829.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $128.86M $125.95M $96.32M
Total non-current assets * $68.55M $94.38M $64.14M
Total assets $197.4M $220.33M $160.46M
Total current liabilities $30.95M $31.6M $28.64M
Total non-current liabilities * $9.27M $33.18M $28.73M
Total equity $157.18M $155.55M $103.08M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$78.32M -$20.08M -$47.11M
Cash from investing $46.22M -$69.77M $48.36M
Cash from financing $26.71M $74.54M -$5.86M
Net change in cash -$5.4M -$15.31M -$4.61M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.